Human Immune Responses Toward HIV-1 Envelope Antigens

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

8 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-03-31

Study Completion Date

2015-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objectives of this study is to

* Define the envelope-specific B-cell and T-cell responses in humans who have received a St. Jude HIV-1 vaccine.
* Describe mechanisms of HIV-1 envelope processing and consequent B-cell and T-cell activities.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Selection of a Protective T Cell-based HIV-1/FIV Vaccine

NCT02389595

HIV

ACTIVE_NOT_RECRUITING

Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen in Children With HIV-1 Infection

NCT00001445

HIV Infection

COMPLETED PHASE1

Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients

NCT00058734

HIV Infections

COMPLETED PHASE1

Evaluation of HIV-Negative Patients With Low CD4+ T Lymphocyte Counts

NCT00001319

CD4 Lymphocytopenia Idiopathic CD4 Positive T Lymphocytopenia

COMPLETED

Evaluate Tolerability of a Multi-envelope, Prime-boost HIV Vaccine in Healthy Adults

NCT00623753

HIV Infections

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The goal of this protocol is to understand how human lymphocytes respond to HIV-1 antigens in the context of vaccination or infection. This protocol will support understanding of the immune response by providing a source of lymphocytes and serum from selected individuals to study in laboratory based investigations. Blood samples from individuals who have received an HIV-1 vaccine, individuals who are HIV-1-infected, and individuals who are HIV-1-uninfected are requested to: (1) test previously vaccinated volunteers for HIV-1 envelope-specific B-cell and T-cell immune activities, and (2) increase understanding of how the human immune system processes and responds to HIV-1 envelope proteins.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

The first group will comprise individuals who have received a St. Jude HIV-1 vaccine and who have exhibited sustained immune responses

No interventions assigned to this group

Group 2

Groups 2 will be HIV-1-infected. The first visit of individuals in groups 2 will involve the collection of 120 ml of blood as well as a minimal blood volume required for the specified screening laboratory evaluation for each group.

No interventions assigned to this group

Group 3

Groups 3 will be HIV-1-uninfected. The first visit of individuals in groups 3 will involve the collection of 120 ml of blood as well as a minimal blood volume required for the specified screening laboratory evaluation for each group.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant is greater than or equal to 18 years of age.
* Participant is in good general health.
* Participant weighs ≥ 110 pounds.
* Participant has hemoglobin \> 12 gm/dL within last 12 weeks.

* Participant has previously received one of the St. Jude HIV-1 vaccines via enrollment in prior St. Jude HIV vaccine studies.

* Participant is HIV-1 positive by medical record review.

* Participant is HIV-1 negative as determined by HIV ELISA.

Exclusion Criteria

* Participant is unable or unwilling to give written informed consent.
* Participant is pregnant female.

* Participant is enrolled in other clinical trials that include any blood sampling such that the cumulative blood draws would exceed that established as constituting minimal risk (e.g., more than 550 ml in an 8 week period with collection more frequently than 2 times per week)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes